Figure 5. Effect of ATA on MDA-MB-453 xenograft tumor growth.
MDA-MB-453 cells (2 × 107 per mouse) were implanted subcutaneously into the right flank of BALB/c nude mice. After solid tumors grew, mice were randomly divided into three groups (n = 6) and treated intraperitoneally with vehicle (negative control group), or ATA (35 mg/kg). Positive control group received lapatinib (80 mg/kg) via gastric gavage twice daily. ATA inhibited tumor growth as measured by tumor volume B. and tumor weight C. without side effects as shown by mice body weight A. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 versus control. D. At the end of the treatment-period, mice were sacrificed and tumors were excised.